CancerParent-FORTNCT06872840
Adapting The Fear Of Recurrence Therapy (FORT) for Parents and Establishing Acceptability and Feasibility
A study testing Parent Fear of Recurrence Therapy (Parent-FORT) in people with Cancer and Parent, run by University of Ottawa at 1 site in Canada.
Trial summary
Clinical levels of fear of cancer recurrence (FCR) affect up to 59% of adult cancer survivors. Family caregivers experience equal or greater levels of FCR, which has been linked to lower quality of life and increased distress. FCR can be addressed in cancer survivors with brief interventions. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Cancer, Parent, Fear of Cancer Recurrence
- What is being tested?
- Parent Fear of Recurrence Therapy (Parent-FORT)
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 36 participants
- Where
- 1 siteCanada
- Study dates
- 26 Aug 2025to 26 May 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Parent (or primary caregiver) caring for a childhood cancer survivor (<18 years of age) of any type of cancer type, who is at least 1 months from the completion of active treatment and has not had a recurrence of their cancer
- A score of 13 or greater on the Fear of Cancer Recurrence Inventory-Short Form-Parent version (FCRI-SF-P; range 0-36), suggesting clinical levels of FCR
- Access to a computer and internet connection
- Living in Canada
Who cannot join
- Being the parent of a pediatric cancer survivor who is now 18 years of age or older
- Being the parent of a pediatric cancer survivor who has undergone hematopoietic cell transplantation and has active chronic or acute graft-versus-host disease which has not stabilized for at least 3 months
- Non-English speakers
- Currently participating in another therapist-led psychosocial therapy group
- Parent with unmanaged/undermanaged mental health disorder judged to be clinically contraindicated and/or likely to affect the group work
- To avoid violating the assumption of nonindependence of the data, only one parent/caregiver per child can participate in the study.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Canada1 site, 1 recruiting
- Recruiting
University of Ottawa
Ottawa, Ontario, K1N6N5
Celeste Holy, B.A., 6135625800, choly@uottawa.ca
Sophie Lebel, PhD, 6135625800 ext. 4811, slebel@uottawa.ca
About this study
Official title: Addressing Fear of Cancer Recurrence in Parents of Pediatric Cancer Survivors: Adapting The Fear Of Recurrence Therapy (FORT) for Parents and Establishing Acceptability and Feasibility
Clinical levels of fear of cancer recurrence (FCR) affect up to 59% of adult cancer survivors. Family caregivers experience equal or greater levels of FCR, which has been linked to lower quality of life and increased distress. FCR can be addressed in cancer survivors with brief interventions. However, none of these interventions have been tested with parents of childhood cancer survivors. This is an urgent gap: the survival rates of childhood cancer have increased more rapidly than for adult cancers, resulting in a growing population of childhood cancer survivors who, along with their families, need support.
The goals of this pilot study are to demonstrate 1) that a newly adapted intervention of FORT (Parent-FORT) is feasible (i.e., participant recruitment, attendance and participation) and acceptable (i.e., parent satisfaction of the intervention) for a larger study, and 2) the clinical implications of Parent-FORT on fear of cancer recurrence (FCR) and quality of life in parents of childhood cancer survivors.
Parents will be randomly assigned to participate in the Parent-FORT intervention immediately or a three-month waitlist control group. They will complete a questionnaire package before and after the intervention, as well as at a three month follow up. This study will help bridge an important gap in bringing evidence-based care to parents who have never been offered help before for their FCR.
Read the detailed description
Pilot Study:
36 parents will be recruited to participate in the study. Additionally, 3 therapists with extensive online support group experience to conduct the Parent-FORT videoconference therapy sessions. Therapist competency to administer Parent-FORT will be determined by registered professionals in counselling or psychotherapy, experience in psychosocial oncology, specifically with parents, and having led at least one group. Interested parents will contact the research coordinator, via telephone or email, to be screened for eligibility and to complete the consent forms. This pilot study will serve as a first step in potential sample size calculations and recruitment times. For this pilot study, active recruitment will last for a period of 15 months during which 36 parents are aimed to be recruited in order to create 4 groups of 9 participants (2 intervention conditions and 2 WLCG). Feasibility of recruitment for the larger RCT will be determined using these criteria: 1) If during our recruitment period less than 18 participants, recruitment for a larger RCT, using our current recruitment strategies, will be deemed not feasible, 2) If between 18 and 25 participants are recruited, then a larger multicentre approach for recruitment will be considered, 3) If recruit 25 participants or more, recruitment for a larger RCT, using our current methods, will be deemed feasible. The sample size will be reevaluated for the larger RCT based on the results from this pilot study.
Parent-FORT consists of 7 consecutive weekly group sessions of 120 minutes each offered through videoconference and weekly assigned homework. Parent-FORT is therapist led, however participants will receive a workbook where they can follow along, take notes, and complete the exercises and the homework assignments. The overall aim of Parent-FORT is to guide Parent towards a more manageable level of worry and fear of recurrence. The key goals are to: 1) distinguish worrisome symptoms from benign ones; 2) identify FCR triggers and inappropriate coping strategies; 3) facilitate the learning and use of new coping strategies, such as relaxation techniques, cognitive restructuring, communication strategies and the use of self-care; 4) increase tolerance for uncertainty; 5) promote emotional expression of specific fears that underlie FCR; and 6) re-examine life priorities and set realistic goals for the future. Each session is composed of exercises where participants have to answer questions, share with the group or watch videos. Furthermore, homework is assigned after each session to be completed before next week's session. Eligible participants will attend a one-on-one pre-therapy meeting with a study therapist to prepare them for the group work (i.e.: review expectations and assess whether group work is appropriate for the participant) and complete the 7-week Parent-FORT intervention. Membership will be closed once groups are formed and the sessions have started to enhance group cohesiveness and consistency. Before starting the intervention, participants will receive a standardized manual describing each session's activities and assignments. All participants (including those in the wait list control group) will complete a questionnaire package pre intervention, post intervention, and at a three month follow up via Qualtrics. Additionally, participants will be asked to complete post session measures, namely the Working Alliance Inventory - Revised Short Form as well as the Group Cohesiveness Scale after the 1st, 4th and 7th sessions.
Therapist Training and Supervision:
To enhance therapist adherence to treatment, the therapists recruited for the study will be provided with a standardized Parent-FORT manual and will be trained by the research psychologists through an online training. The research team will review the video of each session, and the principal investigator will provide weekly 30-minute supervision to the therapists. Furthermore, the study will use an updated version of the fidelity checklist that was used to evaluate adherence during the previous FORT studies. If adherence is less than 80% on any session, the research team will provide additional over-the-telephone feedback to the therapists running the group. This approach to monitoring treatment integrity and fidelity has been successful in previous FORT studies.
Qualitative Assessment:
To gain further insights about the feasibility, acceptability, and potential clinical significance of Parent-FORT, all study participants will be asked to complete semi-structured exit interviews. This will enable a holistic understanding of their experience of Parent-FORT, elucidate key intervention processes, and identify additional secondary outcomes. Lastly, the research coordinator will attempt to interview participants who dropped out of the intervention, to understand any hindering factors. Consenting participants will be asked to complete a semi structured interview (30-60 minutes) about their experience of the intervention through videoconferencing.
Randomization:
This study will use a mixed method randomized control trial design using a waitlist control group and 3 months follow up, with 18 participants per condition. To minimize attrition associated with waiting to enroll participants, block randomization will be used. Specifically, a list of 4 blocks with equal numbers of intervention (I) and wait list control (WLCG) groups (e.g. I-I-WLCG-WLCG; I-WLCG-WLCG-I, etc.) will be randomly created. Once the first 9 participants have been recruited, they will be assigned to whichever group came up first on the list. The next 9 participants will be assigned to the next group on the generated list until all 4 groups have been completed. Participants assigned to the WLCG will be offered the intervention after the 3-month period. To limit bias, each of the 4 blocks of the list will be in separate sealed envelopes that will be opened one at a time after 9 participants have been recruited.
Minimizing Dropouts and Attrition:
To maximize attendance, as in our prior research, participants will be told during informed consent procedures about the importance of attending all 7 sessions to ensure benefit from the intervention. Participants will receive two email reminders about each upcoming session, along with "homework" and session pre-reading materials. They will be asked to inform group therapists if they are to be absent. For participants who miss a session, they will be offered one individual videoconference make-up session for their first missed session before the next group; they will not be offered subsequent make-up sessions for additional missed sessions to decrease the risk that this would encourage those who prefer individualized attention to miss group sessions. Participants who miss more than two sessions will be asked to stop the intervention and restart with the next available group. This approach was successfully tested in previous FORT studies. To minimize differential attrition from the WLCG participants, participants will be emailed monthly with an update about the wait time.
Feasibility and Acceptability Criteria:
The following criteria will be used to assess the feasibility and acceptability of Parent-FORT: 1) ability to recruit 36 parents in 15 months; 2) ability to randomize these 36 parents; 3) ability to deliver Parent-FORT to 27 Parent in 15 months (25% dropout rate); 4) 80% completion of 6 out of the 7 sessions; 5) complete measures for 90% of participants; 6) ability to deliver Parent-FORT as intended as measured by a fidelity rating of above 80% on 75% of reviewed sessions; and 7) Parent satisfactory ratings >than 80% in terms of its content, therapists, and mode of delivery.
Quantitative analysis:
Descriptive statistics will be used to report on FCR outcomes. A linear mixed-effect model analyses will be done on the secondary outcome measures pre- and post-intervention and at the 3-month follow-up. All analyses will use both an intent-to-treat and per protocol approaches. Known extraneous variables that could influence FCR (e.g., age, education, income, cancer stage) will be measured and control for, and monitor for participants' use of any additional psychological support at each data-collection time-points. Dependence of the group data will be analyzed with an intraclass correlation coefficient (p) using a multilevel model.
Qualitative Analysis:
Conventional content analysis will be used to analyse the qualitative data. Interviews will be audiotaped, transcribed verbatim, and managed using the qualitative software program NVivo. Transcripts will be systematically coded into anticipated (e.g., motivations to participate, benefits of participation) and emergent codes. This is an iterative process whereby an initial set of themes are coded, applied to new transcripts, and revised to adjust for new information, until no new codes emerge. Double coding of 80% of the interviews will be done by the research assistant. These codes will then be sorted into subcategories (ideally between 10 to 15).
- Conditions
- Cancer, Parent, Fear of Cancer Recurrence, CBT, Childhood Cancer Survivors
- Being tested
- Parent Fear of Recurrence Therapy (Parent-FORT)
- Keywords
- Pilot study, Group Therapy, Virtual
- Medical subject headings
- Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Parent Fear of Recurrence Therapy (Parent-FORT)Behavioural
7 weekly sessions of 120 minutes each. During the 7 weeks, participants will be asked to participate in activities, participate in group discussions, and complete homework assignments.
| Study group | Role | What they receive |
|---|---|---|
| CBT/Existential Group Therapy for Fear of Cancer Recurrence | Experimental | Participants will receive 7 weekly group therapy sessions consisting of psychoeducation on fear of cancer recurrence, relaxation training, CBT, and evidenced-based tips to decrease avoidance and anxiety surrounding fear of cancer recurrence. Receives: Behavioral: Parent Fear of Recurrence Therapy (Parent-FORT) |
| Waitlist Control Group | No intervention | Participants assigned to this arm will wait about 3-months to receive the intervention. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Changes in baseline fear of cancer recurrence after intervention
Fear of Cancer Recurrence Inventory - Parent (FCRI-P), range from 0-36 with higher scores indicating high levels of fear of cancer recurrence
Measured: Changes in baseline fear of cancer recurrence 7 weeks after the start of the intervention
Changes in baseline fear of cancer recurrence at three months
Fear of Cancer Recurrence Inventory - Parent (FCRI-P), range from 0-36 with higher scores indicating high levels of fear of cancer recurrence
Measured: Changes in baseline fear of cancer recurrence 3 months after the start of the intervention
Secondary outcomes (16)
Changes in Baseline Intolerance of Uncertainty Scale at 7 Weeks
Intolerance of Uncertainty Scale - Short Form (IUS-SF), range from 12-60 with higher scores indicating high levels of intolerance of uncertainty
Measured: Changes in baseline Intolerance of Uncertainty Scale after 7 weeks of the intervention
Changes in Baseline Intolerance of Uncertainty Scale at 3 Months
Intolerance of Uncertainty Scale - Short Form (IUS-SF), range from 12-60 with higher scores indicating high levels of intolerance of uncertainty
Measured: Changes in baseline Intolerance of Uncertainty Scale at 3 month after the completion of the intervention
Changes in baseline Uncertainty in Illness at 7 weeks
Mishel Uncertainty in Illness Scale Short-Form (MUIS-SF), range from 5-25 with higher scores indicating high levels of uncertainty in illness
Measured: Changes in baseline Intolerance of Uncertainty Scale after 7 weeks of the intervention
Changes in baseline Uncertainty in Illness at 3 months
Mishel Uncertainty in Illness Scale Short-Form (MUIS-SF), range from 5-25 with higher scores indicating high levels of uncertainty in illness
Measured: Changes in baseline Intolerance of Uncertainty Scale at 3 month after the completion of the intervention
Changes in baseline Positive Beliefs About Worrying at 7 weeks
Why do people Worry about Health Questionnaire (WW-H), range from 13-65 with higher scores indicating more positive beliefs about worrying
Measured: Changes in baseline Positive Beliefs About Worrying after 7 weeks of the intervention
Changes in baseline Positive Beliefs About Worrying at 3 months
Why do people Worry about Health Questionnaire (WW-H), range from 13-65 with higher scores indicating more positive beliefs about worrying
Measured: Changes in baseline Positive Beliefs About Worrying at 3 month after the completion of the intervention
Changes in baseline avoidance at 7 weeks
Cognitive Avoidance Questionnaire (CAQ), range from 25-125 with higher scores indicating higher use of avoidance as a coping strategy
Measured: Changes in baseline avoidance after 7 weeks of the intervention
Changes in baseline avoidance at 3 months
Cognitive Avoidance Questionnaire (CAQ), range from 25-125 with higher scores indicating higher use of avoidance as a coping strategy
Measured: Changes in baseline Avoidance at 3 month after the completion of the intervention
Changes in fear of bodily threat at 7 weeks
Bodily Threat Inventory-Parent (BTI-Parent), range from 30-150 with higher scores indicating higher levels of fear
Measured: Changes in fear of bodily threat after 7 weeks of the intervention
Changes in fear of bodily threat at 3 months
Bodily Threat Inventory-Parent (BTI-Parent), range from 30-150 with higher scores indicating higher levels of fear
Measured: Changes in fear of bodily threat at 3 month after the completion of the intervention
Changes in healthcare utilization at 3 months
Healthcare Utilization Questionnaire. Parents will report on the number of times in the past 3 months that they used medical services for their child
Measured: Changes in healthcare utilization at 3 month after the completion of the intervention
Changes in quality of life at 7 weeks
The EuroQol Five Dimensional Questionnaire (EQ-5D) is a 5-item quality of life measure. Score from 1-5 in each dimension. Higher scores indicates lower quality of life.
Measured: Changes in quality of life after 7 weeks of the intervention
Changes in quality of life at 3 months
The EuroQol Five Dimensional Questionnaire (EQ-5D) is a 5-item quality of life measure (EQ-5D). Score from 1-5 in each dimension. Higher score indicates lower quality of life.
Measured: Changes in quality of life at 3 month after the completion of the intervention
Changes in perceived risk of recurrence at 7 weeks
Perceived risk of recurrence will be assessed using a one-item question
Measured: Changes in perceived risk of recurrence after 7 weeks of the intervention
Changes in perceived risk of recurrence at 3 months
Perceived risk of recurrence will be assessed using a one-item question
Measured: Changes in perceived risk of recurrence 3 month after the completion of the intervention
Measure of acceptability/satisfaction at 7 weeks
Treatment Acceptability and Preferences (TAP) measure, range from 4-20, with higher scores indicating greater acceptability/satisfaction.
Measured: Measure of acceptability/satisfaction after 7 weeks of the intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Mar 2025
- Study start26 Aug 2025
- Primary completion26 Aug 2026 (estimated)
- Study completion26 May 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 36 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Ottawa
- Sponsor type
- University, hospital or other
- Collaborators
- Children's Hospital of Eastern Ontario, Alberta Children's Hospital
- Responsible party
- Principal investigator, Sophie Lebel, University of Ottawa
- Investigators
- Sophie Lebel, PhD, Principal investigator, University of Ottawa
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06872840
- Sponsor's protocol ID
- H-08-24-10241
- Other IDs
- 506459
- Acronym
- Parent-FORT
- Status last verified
- Sep 2025
- First submitted
- 1 Mar 2025
- Last updated
- 22 Sep 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Lamarche J, Nissim R, Avery J, Wong J, Maheu C, Lambert SD, Laizner AM, Jones J, Esplen MJ, Lebel S. It is Time to Address Fear of Cancer Recurrence in Family Caregivers: Feasibility and Acceptability of a Randomized Pilot Study of the Family Caregiver Version of the Fear of Recurrence Therapy (FC-FORT). Psychooncology. 2025 Feb;34(2):e70084. doi: 10.1002/pon.70084.
PubMed 39887474Murphy LK, Heathcote LC, Prussien KV, Rodriguez EM, Hewitt JA, Schwartz LE, Ferrante AC, Gerhardt CA, Vannatta K, Compas BE. Mother-child communication about possible cancer recurrence during childhood cancer survivorship. Psychooncology. 2021 Apr;30(4):536-545. doi: 10.1002/pon.5600. Epub 2020 Dec 3.
PubMed 33227159Webb K, Sharpe L, Butow P, Dhillon H, Zachariae R, Tauber NM, O'Toole MS, Shaw J. Caregiver fear of cancer recurrence: A systematic review and meta-analysis of quantitative studies. Psychooncology. 2023 Aug;32(8):1173-1191. doi: 10.1002/pon.6176. Epub 2023 Jun 11.
PubMed 37303263Simard S, Thewes B, Humphris G, Dixon M, Hayden C, Mireskandari S, Ozakinci G. Fear of cancer recurrence in adult cancer survivors: a systematic review of quantitative studies. J Cancer Surviv. 2013 Sep;7(3):300-22. doi: 10.1007/s11764-013-0272-z. Epub 2013 Mar 10.
PubMed 23475398Lebel S, Ozakinci G, Humphris G, Mutsaers B, Thewes B, Prins J, Dinkel A, Butow P; University of Ottawa Fear of Cancer Recurrence Colloquium attendees. From normal response to clinical problem: definition and clinical features of fear of cancer recurrence. Support Care Cancer. 2016 Aug;24(8):3265-8. doi: 10.1007/s00520-016-3272-5. Epub 2016 May 12.
PubMed 27169703
Study at a glance
From the registry record, last updated by the sponsor on 22 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Addressing Fear of Cancer Recurrence in Parents of Pediatric Cancer Survivors: Adapting The Fear Of Recurrence Therapy (FORT) for Parents and Establishing Acceptability and Feasibility
- ClinicalTrials.gov ID
- NCT06872840
- Acronym / sponsor ID
- Parent-FORT / H-08-24-10241
- Conditions
- Cancer, Parent, Fear of Cancer Recurrence, CBT, Childhood Cancer Survivors
- Keywords
- Pilot study, Group Therapy, Virtual
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 36 participants (estimated)
- Lead sponsor
- University of OttawaUniversity, hospital or other
- Collaborators
- Children's Hospital of Eastern Ontario, Alberta Children's Hospital
- Study start
- 26 Aug 2025 (actual)
- Primary completion
- 26 Aug 2026 (estimated)
- Study completion
- 26 May 2027 (estimated)
- First posted
- 12 Mar 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Clinical levels of fear of cancer recurrence (FCR) affect up to 59% of adult cancer survivors. Family caregivers experience equal or greater levels of FCR, which has been linked to lower quality of life and increased distress. FCR can be addressed in cancer survivors with brief interventions. However, none of these interventions have been tested with parents of childhood cancer survivors. This is an urgent gap: the survival rates of childhood cancer have increased more rapidly than for adult cancers, resulting in a growing population of childhood cancer survivors who, along with their families, need support.
The goals of this pilot study are to demonstrate 1) that a newly adapted intervention of FORT (Parent-FORT) is feasible (i.e., participant recruitment, attendance and participation) and acceptable (i.e., parent satisfaction of the intervention) for a larger study, and 2) the clinical implications of Parent-FORT on fear of cancer recurrence (FCR) and quality of life in parents of childhood cancer survivors.
Parents will be randomly assigned to participate in the Parent-FORT intervention immediately or a three-month waitlist control group. They will complete a questionnaire package before and after the intervention, as well as at a three month follow up. This study will help bridge an important gap in bringing evidence-based care to parents who have never been offered help before for their FCR.
Detailed description
Pilot Study:
36 parents will be recruited to participate in the study. Additionally, 3 therapists with extensive online support group experience to conduct the Parent-FORT videoconference therapy sessions. Therapist competency to administer Parent-FORT will be determined by registered professionals in counselling or psychotherapy, experience in psychosocial oncology, specifically with parents, and having led at least one group. Interested parents will contact the research coordinator, via telephone or email, to be screened for eligibility and to complete the consent forms. This pilot study will serve as a first step in potential sample size calculations and recruitment times. For this pilot study, active recruitment will last for a period of 15 months during which 36 parents are aimed to be recruited in order to create 4 groups of 9 participants (2 intervention conditions and 2 WLCG). Feasibility of recruitment for the larger RCT will be determined using these criteria: 1) If during our recruitment period less than 18 participants, recruitment for a larger RCT, using our current recruitment strategies, will be deemed not feasible, 2) If between 18 and 25 participants are recruited, then a larger multicentre approach for recruitment will be considered, 3) If recruit 25 participants or more, recruitment for a larger RCT, using our current methods, will be deemed feasible. The sample size will be reevaluated for the larger RCT based on the results from this pilot study.
Parent-FORT consists of 7 consecutive weekly group sessions of 120 minutes each offered through videoconference and weekly assigned homework. Parent-FORT is therapist led, however participants will receive a workbook where they can follow along, take notes, and complete the exercises and the homework assignments. The overall aim of Parent-FORT is to guide Parent towards a more manageable level of worry and fear of recurrence. The key goals are to: 1) distinguish worrisome symptoms from benign ones; 2) identify FCR triggers and inappropriate coping strategies; 3) facilitate the learning and use of new coping strategies, such as relaxation techniques, cognitive restructuring, communication strategies and the use of self-care; 4) increase tolerance for uncertainty; 5) promote emotional expression of specific fears that underlie FCR; and 6) re-examine life priorities and set realistic goals for the future. Each session is composed of exercises where participants have to answer questions, share with the group or watch videos. Furthermore, homework is assigned after each session to be completed before next week's session. Eligible participants will attend a one-on-one pre-therapy meeting with a study therapist to prepare them for the group work (i.e.: review expectations and assess whether group work is appropriate for the participant) and complete the 7-week Parent-FORT intervention. Membership will be closed once groups are formed and the sessions have started to enhance group cohesiveness and consistency. Before starting the intervention, participants will receive a standardized manual describing each session's activities and assignments. All participants (including those in the wait list control group) will complete a questionnaire package pre intervention, post intervention, and at a three month follow up via Qualtrics. Additionally, participants will be asked to complete post session measures, namely the Working Alliance Inventory - Revised Short Form as well as the Group Cohesiveness Scale after the 1st, 4th and 7th sessions.
Therapist Training and Supervision:
To enhance therapist adherence to treatment, the therapists recruited for the study will be provided with a standardized Parent-FORT manual and will be trained by the research psychologists through an online training. The research team will review the video of each session, and the principal investigator will provide weekly 30-minute supervision to the therapists. Furthermore, the study will use an updated version of the fidelity checklist that was used to evaluate adherence during the previous FORT studies. If adherence is less than 80% on any session, the research team will provide additional over-the-telephone feedback to the therapists running the group. This approach to monitoring treatment integrity and fidelity has been successful in previous FORT studies.
Qualitative Assessment:
To gain further insights about the feasibility, acceptability, and potential clinical significance of Parent-FORT, all study participants will be asked to complete semi-structured exit interviews. This will enable a holistic understanding of their experience of Parent-FORT, elucidate key intervention processes, and identify additional secondary outcomes. Lastly, the research coordinator will attempt to interview participants who dropped out of the intervention, to understand any hindering factors. Consenting participants will be asked to complete a semi structured interview (30-60 minutes) about their experience of the intervention through videoconferencing.
Randomization:
This study will use a mixed method randomized control trial design using a waitlist control group and 3 months follow up, with 18 participants per condition. To minimize attrition associated with waiting to enroll participants, block randomization will be used. Specifically, a list of 4 blocks with equal numbers of intervention (I) and wait list control (WLCG) groups (e.g. I-I-WLCG-WLCG; I-WLCG-WLCG-I, etc.) will be randomly created. Once the first 9 participants have been recruited, they will be assigned to whichever group came up first on the list. The next 9 participants will be assigned to the next group on the generated list until all 4 groups have been completed. Participants assigned to the WLCG will be offered the intervention after the 3-month period. To limit bias, each of the 4 blocks of the list will be in separate sealed envelopes that will be opened one at a time after 9 participants have been recruited.
Minimizing Dropouts and Attrition:
To maximize attendance, as in our prior research, participants will be told during informed consent procedures about the importance of attending all 7 sessions to ensure benefit from the intervention. Participants will receive two email reminders about each upcoming session, along with "homework" and session pre-reading materials. They will be asked to inform group therapists if they are to be absent. For participants who miss a session, they will be offered one individual videoconference make-up session for their first missed session before the next group; they will not be offered subsequent make-up sessions for additional missed sessions to decrease the risk that this would encourage those who prefer individualized attention to miss group sessions. Participants who miss more than two sessions will be asked to stop the intervention and restart with the next available group. This approach was successfully tested in previous FORT studies. To minimize differential attrition from the WLCG participants, participants will be emailed monthly with an update about the wait time.
Feasibility and Acceptability Criteria:
The following criteria will be used to assess the feasibility and acceptability of Parent-FORT: 1) ability to recruit 36 parents in 15 months; 2) ability to randomize these 36 parents; 3) ability to deliver Parent-FORT to 27 Parent in 15 months (25% dropout rate); 4) 80% completion of 6 out of the 7 sessions; 5) complete measures for 90% of participants; 6) ability to deliver Parent-FORT as intended as measured by a fidelity rating of above 80% on 75% of reviewed sessions; and 7) Parent satisfactory ratings >than 80% in terms of its content, therapists, and mode of delivery.
Quantitative analysis:
Descriptive statistics will be used to report on FCR outcomes. A linear mixed-effect model analyses will be done on the secondary outcome measures pre- and post-intervention and at the 3-month follow-up. All analyses will use both an intent-to-treat and per protocol approaches. Known extraneous variables that could influence FCR (e.g., age, education, income, cancer stage) will be measured and control for, and monitor for participants' use of any additional psychological support at each data-collection time-points. Dependence of the group data will be analyzed with an intraclass correlation coefficient (p) using a multilevel model.
Qualitative Analysis:
Conventional content analysis will be used to analyse the qualitative data. Interviews will be audiotaped, transcribed verbatim, and managed using the qualitative software program NVivo. Transcripts will be systematically coded into anticipated (e.g., motivations to participate, benefits of participation) and emergent codes. This is an iterative process whereby an initial set of themes are coded, applied to new transcripts, and revised to adjust for new information, until no new codes emerge. Double coding of 80% of the interviews will be done by the research assistant. These codes will then be sorted into subcategories (ideally between 10 to 15).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| CBT/Existential Group Therapy for Fear of Cancer Recurrence | Experimental | Behavioral: Parent Fear of Recurrence Therapy (Parent-FORT)Participants will receive 7 weekly group therapy sessions consisting of psychoeducation on fear of cancer recurrence, relaxation training, CBT, and evidenced-based tips to decrease avoidance and anxiety surrounding fear of cancer recurrence. |
| Waitlist Control Group | No intervention | –Participants assigned to this arm will wait about 3-months to receive the intervention. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Parent (or primary caregiver) caring for a childhood cancer survivor (<18 years of age) of any type of cancer type, who is at least 1 months from the completion of active treatment and has not had a recurrence of their cancer
- A score of 13 or greater on the Fear of Cancer Recurrence Inventory-Short Form-Parent version (FCRI-SF-P; range 0-36), suggesting clinical levels of FCR
- Access to a computer and internet connection
- Living in Canada
Key exclusion criteria (6 listed)
- Being the parent of a pediatric cancer survivor who is now 18 years of age or older
- Being the parent of a pediatric cancer survivor who has undergone hematopoietic cell transplantation and has active chronic or acute graft-versus-host disease which has not stabilized for at least 3 months
- Non-English speakers
- Currently participating in another therapist-led psychosocial therapy group
- Parent with unmanaged/undermanaged mental health disorder judged to be clinically contraindicated and/or likely to affect the group work
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Parent Fear of Recurrence Therapy (Parent-FORT)7 weekly sessions of 120 minutes each. During the 7 weeks, participants will be asked to participate in activities, participate in group discussions, and complete homework assignments. | Behavioural | CBT/Existential Group Therapy for Fear of Cancer Recurrence |
Primary outcome
Changes in baseline fear of cancer recurrence after intervention
Time frame: Changes in baseline fear of cancer recurrence 7 weeks after the start of the intervention
Fear of Cancer Recurrence Inventory - Parent (FCRI-P), range from 0-36 with higher scores indicating high levels of fear of cancer recurrence
Changes in baseline fear of cancer recurrence at three months
Time frame: Changes in baseline fear of cancer recurrence 3 months after the start of the intervention
Fear of Cancer Recurrence Inventory - Parent (FCRI-P), range from 0-36 with higher scores indicating high levels of fear of cancer recurrence
16 secondary outcomes
Changes in Baseline Intolerance of Uncertainty Scale at 7 Weeks
Time frame: Changes in baseline Intolerance of Uncertainty Scale after 7 weeks of the intervention
Changes in Baseline Intolerance of Uncertainty Scale at 3 Months
Time frame: Changes in baseline Intolerance of Uncertainty Scale at 3 month after the completion of the intervention
Changes in baseline Uncertainty in Illness at 7 weeks
Time frame: Changes in baseline Intolerance of Uncertainty Scale after 7 weeks of the intervention
Changes in baseline Uncertainty in Illness at 3 months
Time frame: Changes in baseline Intolerance of Uncertainty Scale at 3 month after the completion of the intervention
Changes in baseline Positive Beliefs About Worrying at 7 weeks
Time frame: Changes in baseline Positive Beliefs About Worrying after 7 weeks of the intervention
Changes in baseline Positive Beliefs About Worrying at 3 months
Time frame: Changes in baseline Positive Beliefs About Worrying at 3 month after the completion of the intervention
Changes in baseline avoidance at 7 weeks
Time frame: Changes in baseline avoidance after 7 weeks of the intervention
Changes in baseline avoidance at 3 months
Time frame: Changes in baseline Avoidance at 3 month after the completion of the intervention
Changes in fear of bodily threat at 7 weeks
Time frame: Changes in fear of bodily threat after 7 weeks of the intervention
Changes in fear of bodily threat at 3 months
Time frame: Changes in fear of bodily threat at 3 month after the completion of the intervention
Changes in healthcare utilization at 3 months
Time frame: Changes in healthcare utilization at 3 month after the completion of the intervention
Changes in quality of life at 7 weeks
Time frame: Changes in quality of life after 7 weeks of the intervention
Changes in quality of life at 3 months
Time frame: Changes in quality of life at 3 month after the completion of the intervention
Changes in perceived risk of recurrence at 7 weeks
Time frame: Changes in perceived risk of recurrence after 7 weeks of the intervention
Changes in perceived risk of recurrence at 3 months
Time frame: Changes in perceived risk of recurrence 3 month after the completion of the intervention
Measure of acceptability/satisfaction at 7 weeks
Time frame: Measure of acceptability/satisfaction after 7 weeks of the intervention
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Sep 2025.
- Background: PubMed 39887474Lamarche J, Nissim R, Avery J, Wong J, Maheu C, Lambert SD, Laizner AM, Jones J, Esplen MJ, Lebel S. It is Time to Address Fear of Cancer Recurrence in Family Caregivers: Feasibility and Acceptability of a Randomized Pilot Study of the Family Caregiver Version of the Fear of Recurrence Therapy (FC-FORT). Psychooncology. 2025 Feb;34(2):e70084. doi: 10.1002/pon.70084.
- Background: PubMed 33227159Murphy LK, Heathcote LC, Prussien KV, Rodriguez EM, Hewitt JA, Schwartz LE, Ferrante AC, Gerhardt CA, Vannatta K, Compas BE. Mother-child communication about possible cancer recurrence during childhood cancer survivorship. Psychooncology. 2021 Apr;30(4):536-545. doi: 10.1002/pon.5600. Epub 2020 Dec 3.
- Background: PubMed 37303263Webb K, Sharpe L, Butow P, Dhillon H, Zachariae R, Tauber NM, O'Toole MS, Shaw J. Caregiver fear of cancer recurrence: A systematic review and meta-analysis of quantitative studies. Psychooncology. 2023 Aug;32(8):1173-1191. doi: 10.1002/pon.6176. Epub 2023 Jun 11.
- Background: PubMed 23475398Simard S, Thewes B, Humphris G, Dixon M, Hayden C, Mireskandari S, Ozakinci G. Fear of cancer recurrence in adult cancer survivors: a systematic review of quantitative studies. J Cancer Surviv. 2013 Sep;7(3):300-22. doi: 10.1007/s11764-013-0272-z. Epub 2013 Mar 10.
- Background: PubMed 27169703Lebel S, Ozakinci G, Humphris G, Mutsaers B, Thewes B, Prins J, Dinkel A, Butow P; University of Ottawa Fear of Cancer Recurrence Colloquium attendees. From normal response to clinical problem: definition and clinical features of fear of cancer recurrence. Support Care Cancer. 2016 Aug;24(8):3265-8. doi: 10.1007/s00520-016-3272-5. Epub 2016 May 12.
- Related InfoLink provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Sophie Lebel, PhD principal investigator
University of Ottawa
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Parent Fear of Recurrence Therapy (Parent-FORT) in people with Cancer and Parent, run by University of Ottawa at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 22 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Celeste Holy, B.A (6135625800, choly@uottawa.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Changes in baseline fear of cancer recurrence after intervention (time frame: Changes in baseline fear of cancer recurrence 7 weeks after the start of the intervention). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06872840, which also lists 5 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Sep 2025.